Sai Parenterals targets ₹750 crore revenue after Noumed integration
The pharmaceutical firm reported a 167% jump in quarterly revenue to ₹198 crore. This follows the first full-year consolidation of its Australian subsidiary.
What's new
- Q4 consolidated revenue hit ₹198 crore, a 167% increase year-on-year.
- Full-year profit reached ₹14.4 crore, rising 46% after the Noumed acquisition.
- Management targets ₹750 crore revenue and 17% EBITDA margins for FY27.
Why this matters
The revenue jump reflects the impact of the Noumed acquisition. The aggressive guidance for FY27 hinges on a ₹440 crore capex plan, which exceeds the company's entire revenue for the year just ended. This is a high-stakes bet on capacity expansion.
What we're watching
- Execution of the ₹440 crore capex program across Indian and Australian sites.
- Whether EBITDA margins hold at the targeted 17% level.
- Integration progress of the Noumed business in the coming quarters.
The full read
Sai Parenterals is betting on international expansion. After a year where consolidated revenue climbed 140% to ₹381 crore—largely due to the full integration of its Australian subsidiary, Noumed, the company is now targeting ₹750 crore in revenue for FY27. To reach this, management committed to a ₹440 crore capex program spanning its Indian and Australian facilities. The Q4 results show the momentum, with consolidated revenue of ₹198 crore and net profit of ₹13.3 crore. While the standalone business remains profitable with a 64% profit jump to ₹16.9 crore, the group's future is tied to the success of this capital-intensive strategy. The next test is whether the company can maintain its targeted 17% EBITDA margin while managing such a large increase in infrastructure investment.
Questions answered
- What drove the surge in Sai Parenterals' financial performance?
- The primary driver was the first full-year consolidation of Noumed, an Australian subsidiary acquired in November. This integration helped push full-year revenue to ₹381 crore, a 140% increase.
- How much does the company plan to spend on capital expenditure?
- Management plans to invest roughly ₹440 crore in capital expenditure. This spending is allocated across both Indian and Australian facilities.
- What are the specific financial targets for the current fiscal year?
- The company has issued guidance for ₹750 crore in revenue for FY27. It also projects EBITDA margins of 17%.
- How did the standalone business perform compared to the consolidated results?
- The standalone business grew at a slower pace than the consolidated group. Revenue increased 31% to ₹165 crore and profit rose 64% to ₹16.9 crore.